PBAC Public Summary Documents – December 2024

Page last updated: 11 April 2025

Public Summary Documents relating to the December 2024 PBAC meeting.

• Aripiprazole: I.M. injection (modified release) 720 mg in 2.4 mL pre-filled syringe, I.M. injection (modified release) 960 mg in 3.2 mL pre-filled syringe; Abilify Asimtufii® – December 2024

The following Public Summary Documents have been updated:

March 2024 PBAC Meeting

• Adalimumab (IMID): Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled pen; Humira®
• Dabrafenib and Trametinib: Dabrafenib: Capsule 50 mg (as mesilate), Capsule 75 mg (as mesilate), Tablet (dispersible) 10 mg; Tafinlar®; Trametinib: Tablet 500 micrograms, Tablet 2 mg, Powder for oral solution 5 micrograms per mL (as dimethylsulfoxide), 97 mL; Mekinist®

July 2024 PBAC Meeting

• Esketamine: Nasal spray solution 28 mg in 0.2 mL (2 actuations); Spravato®Esketamine: Nasal spray solution 28 mg in 0.2 mL (2 actuations); Spravato®